Answers are grounded in this paper and cite their sources.
The article reviews and analyzes 63 scientific publications devoted to new classes of antituberculosis drugs – DprE1 inhibitors. Currently, compounds BTZ-043, PBTZ-169 (makozinone), TBA-7371 and OPC-167832 are tested at different stages of clinical trials. DprE1 inhibitors are promising drugs with antituberculosis activity, which requires further clinical trials.
No takes yet. Share an insight, caveat, or question.
А. V. Kukurika (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: